New Report: Monoclonal Antibodies in the Pipeline

March 24, 2011 - PRLog -- NEEDHAM, MA. – Cambridge Healthtech Institute’s Insight Pharma Reports announces the Monoclonal Antibodies in the Pipeline: A Segment of Major Growth Report, authored by Peter Norman, MBA, PhD.

Monoclonal antibodies are highly valuable therapeutic agents and were among the best-selling drugs in the world in 2010. Global revenues from monoclonal antibody products will have moved significantly past the $40 billion level in 2010 and are poised to continue growing steadily through to 2015.   This report focuses on:

- Nearly 300 monoclonal antibodies currently in clinical development, organized by indication and/or target
- Sales of currently marketed monoclonal antibodies, market share by company, and projected market growth
- Anticipated filing dates for prospective products and their commercial prospects
- Threats such as reimbursement constraints and the emergence of biosimilar products
- Enabling and emerging technologies for optimization of therapeutic monoclonal antibodies
- Corporate profiles of monoclonal antibody product-focused and technology-focused companies

For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com

About Insight Pharma Reports (http://www.InsightPharmaReports.com)
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.  http://www.InsightPharmaReports.com

# # #

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.